Treatment Should Be Initiated Despite FRAX Below 20%
In this 78-year-old woman with a lumbar spine T-score of -2.0 and hip T-score of -1.5, pharmacologic therapy should be initiated even though the FRAX hip fracture risk is 18%, because her age (78 years) combined with osteopenia (T-score between -1.0 and -2.5) places her at high risk, and current guidelines support treatment based on multiple risk factors beyond FRAX thresholds alone. 1, 2, 1
Why Treatment Is Indicated
Age as a Critical Risk Factor
At 78 years old, this patient falls into a category where age itself substantially elevates fracture risk independent of FRAX scores. The AACE/ACE 2020 guidelines explicitly state that indicators of very high fracture risk include "advanced age" and "frailty" even when FRAX scores don't meet traditional thresholds 1, 2. The guidelines recognize that FRAX may underestimate risk in older individuals 3.
T-Score Considerations
While her T-scores don't meet the -2.5 threshold for osteoporosis diagnosis, she has documented osteopenia (T-scores between -1.0 and -2.5) at both spine and hip. The AACE guidelines recommend pharmacologic therapy for patients with T-scores in this range when additional risk factors are present 1, 2, 1.
The 18% FRAX Score Context
Although 18% is technically below the 20% major osteoporotic fracture threshold, this is dangerously close to the treatment threshold and should not be viewed as reassuring in a 78-year-old. Research demonstrates that FRAX-based thresholds can identify the majority of women who will sustain fractures, but age-dependent thresholds may be more appropriate than fixed cutoffs 4. Additionally, studies show that most fractures occur in women without osteoporosis by BMD criteria alone, emphasizing the importance of comprehensive risk assessment 5.
Recommended Treatment Approach
First-Line Pharmacotherapy
Initiate oral bisphosphonate therapy (alendronate 70 mg weekly or risedronate 35 mg weekly) as first-line treatment 1, 2, 6. These agents:
- Reduce hip, nonvertebral, and spine fractures
- Are cost-effective with generic formulations available
- Have Grade A evidence for efficacy 1, 2
Alternative Options
If oral bisphosphonates are contraindicated or not tolerated:
Essential Concurrent Interventions
Optimize Vitamin D Status
Her vitamin D level of 50 ng/mL is adequate (above the recommended 20 ng/mL threshold 8), so maintain current vitamin D supplementation at 400-800 IU daily 8, 9.
Calcium Intake
Ensure 1,200 mg calcium daily (dietary plus supplementation) as recommended for women over 70 8, 9.
Fall Prevention Strategy
At 78 years, fall risk assessment is critical:
- Implement balance and resistance training twice weekly 1, 2, 9
- Evaluate home safety and mobility aids
- Review medications that increase fall risk 1
Monitoring Plan
Bone Density Surveillance
- Repeat DXA in 1-2 years to assess treatment response 1, 2, 1
- Continue monitoring every 1-2 years until stable 1
Treatment Duration
- Plan for 5 years of oral bisphosphonate therapy initially 7, 6
- Reassess fracture risk at 5 years to determine if drug holiday is appropriate 7, 6
Critical Pitfalls to Avoid
Do not rely solely on FRAX thresholds in elderly patients. The 20% cutoff is a guideline, not an absolute rule, and multiple factors beyond FRAX influence treatment decisions 1, 2, 3. In this 78-year-old with documented osteopenia, the combination of age, bone density, and near-threshold FRAX score creates a compelling case for intervention.
Do not delay treatment waiting for further bone loss. At this age, preventing the first fracture is paramount, as any fracture significantly increases risk of subsequent fractures and associated morbidity and mortality 10.
Ensure adherence strategies are in place. Bisphosphonates require specific administration instructions (take on empty stomach, remain upright 30 minutes), and poor adherence is common. Consider IV zoledronic acid if adherence concerns exist 1, 6.